NXTP — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
CellRep develops an AI-powered platform that discovers small molecules to reprogram exhausted immune cells, enhancing their function for therapeutic applications including cancer immunotherapy and chronic viral infections.
AI & Machine LearningBiotechLongevity
Alfonso Amat(CEO & Co-Founder)inFederico Perdomo Celis(CSO & Co-Founder)inManuel Franco Cortés(CCO & Co-Founder)Julian Ganzabal(CAIO & Co-Founder)in
Co-investorsAIR CapitalGRIDXRiverwood Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Surus AI
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.